<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144419">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01654185</url>
  </required_header>
  <id_info>
    <org_study_id>Fudan BR2012-12</org_study_id>
    <nct_id>NCT01654185</nct_id>
  </id_info>
  <brief_title>Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer</brief_title>
  <official_title>Phase II Study of Dimethyldiguanide Combined With AI Compared to AI in Postmenopausal HR(+) Metastatic Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xichun Hu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The addition of dimethyldiguanide might increase the efficacy of AI treatment in metastatic
      breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The addition of dimethyldiguanide might increase the efficacy of AI in patients with
      metastatic breast cancer after the failure of the first line endocrine therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>AI plus Dimethyldiguanide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AI 1 tablet qd plus Dimethyldiguanide 0.5 bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aromatase Inhibitor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AI monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AI plus Dimethyldiguanide</intervention_name>
    <description>AI 1 tablet per day Dimethyldiguanide 0.5 bid</description>
    <arm_group_label>AI plus Dimethyldiguanide</arm_group_label>
    <other_name>letrozole or exemestane</other_name>
    <other_name>Dimethyldiguanide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aromatase Inhibitor</intervention_name>
    <description>1 tablet per day</description>
    <arm_group_label>Aromatase Inhibitor</arm_group_label>
    <other_name>letrozole or exemestane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  postmenopausal HR positive breast cancer patients;

          -  inoperable locally advanced or metastatic breast cancer patients;

          -  candidate for endocrine therapy;

          -  ECOG equal to or less than 1;

          -  adequate bone marrow function(Hb&gt;=90g/L, WBC &gt;=3.5×10^9/L,ANC&gt;=1.5×10^9/L,
             PLT&gt;=80×10^9/L; adequate renal function(Ccr&lt;=ULN);adequate liver
             function(ALT,AST,AKP&lt;=2.5*ULN,or &lt;=5*ULN if liver metastases)

          -  life expectancy &gt;=12weeks;

          -  no severe history disease of liver,heart,lung or kidney;

          -  written informed consent form;

        Exclusion Criteria:

          -  Her-2 overexpression;

          -  patients who has visceral endocrisis；
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xichun Hu, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xichun Hu, MD, PhD</last_name>
    <phone>64175590</phone>
    <phone_ext>5006</phone_ext>
    <email>huxicun@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Biyun Wang, MD</last_name>
    <phone>64175590</phone>
    <phone_ext>5000</phone_ext>
    <email>wangbiyun@msn.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xichun Hu, MD,PhD</last_name>
      <phone>64175590</phone>
      <phone_ext>5006</phone_ext>
      <email>huxicun@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Biyun Wang, MD</last_name>
      <phone>64175590</phone>
      <phone_ext>5000</phone_ext>
      <email>wangbiyun@msn.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>July 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xichun Hu</investigator_full_name>
    <investigator_title>Deputy director of department of medical oncology</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
